ArticleAlimentary pharmacology & therapeutics2018
Retraction: Randomised clinical trial: The clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China by J. Sun, C. Yang, H. Zhao, P. Zheng, J. Wilkinson, B. Ng, Y. Yuan. Aliment Pharmacol Ther. 2015;42:845-854.
Article in Alimentary pharmacology & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction of
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The above article from Alimentary Pharmacology & Therapeutics, published online on 31 July 2015 on Wiley Online Library (wileyonlinelibrary.com), and in Volume 42, pp. 845-854, has been retracted by agreement between the authors, J. Sun, C. Yang, H. Zhao, P. Zheng, J. Wilkinson, B. Ng and Y. Yuan, the journal Editors in Chief, J. M. Rhodes and C. W. Howden, and John Wiley Sons Ltd. The retraction has been agreed upon following major protocol deviations at some study sites and several instances of non-compliance that are sufficiently serious to warrant the withdrawal of the Chinese New Drug Application for Gaviscon Double Action.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.